Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jan 16;8(1):e2613.
doi: 10.1371/journal.pntd.0002613. eCollection 2014.

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial

Eltahir A G Khalil  1 , Teklu Weldegebreal  2 , Brima M Younis  1 , Raymond Omollo  3 , Ahmed M Musa  1 , Workagegnehu Hailu  4 , Abuzaid A Abuzaid  1 , Thomas P C Dorlo  5 , Zewdu Hurissa  4 , Sisay Yifru  4 , William Haleke  2 , Peter G Smith  6 , Sally Ellis  7 , Manica Balasegaram  7 , Ahmed M EL-Hassan  1 , Gerard J Schoone  8 , Monique Wasunna  9 , Robert Kimutai  9 , Tansy Edwards  6 , Asrat Hailu  10
Affiliations
Randomized Controlled Trial

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial

Eltahir A G Khalil et al. PLoS Negl Trop Dis. .

Abstract

Background: Anti-leishmanial drug regimens that include a single dose AmBisome could be suitable for eastern African patients with symptomatic visceral leishmaniasis (VL) but the appropriate single dose is unknown.

Methodology: A multi-centre, open-label, non-inferiority, randomized controlled trial with an adaptive design, was conducted to compare the efficacy and safety of a single dose and multiple doses of AmBisome for the treatment of VL in eastern Africa. The primary efficacy endpoint was definitive cure (DC) at 6 months. Symptomatic patients with parasitologically-confirmed, non-severe VL, received a single dose of AmBisome 7.5 mg/kg body weight or multiple doses, 7 times 3 mg/kg on days 1-5, 14, and 21. If interim analyses, evaluated 30 days after the start of treatment following 40 or 80 patients, showed the single dose gave significantly poorer parasite clearance than multiple doses at the 5% significance level, the single dose was increased by 2·5 mg/kg. In a sub-set of patients, parasite clearance was measured by quantitative reverse transcriptase (qRT) PCR.

Principal findings: The trial was terminated after the third interim analysis because of low efficacy of both regimens. Based on the intention-to-treat population, DC was 85% (95%CI 73-93%), 40% (95%CI 19-64%), and 58% (95%CI 41-73%) in patients treated with multiple doses (n = 63), and single doses of 7·5 (n = 21) or 10 mg/kg (n = 40), respectively. qRT-PCR suggested superior parasite clearance with multiple doses as early as day 3. Safety data accorded with the drug label.

Conclusions: The tested AmBisome regimens would not be suitable for VL treatment across eastern Africa. An optimal single dose regimen was not identified.

Trials registration: www.clinicaltrials.govNCT00832208.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist. Gilead Sciences, USA, provided the investigational product, AmBisome®. Gilead Sciences and the sponsors, DNDi, have professional collaborations. This collaboration does not alter our adherence to all PLOS NTDs policies on sharing data and materials.

Figures

Figure 1
Figure 1. Patient flow chart.
Consort Patient flow chart: AmBisome® multi dose vs. single dose, ITT Intention to treat, PP per protocol, LTFU Lost to Follow-up.
Figure 2
Figure 2. Summary of study design.
Interim analyses were based on day 30 cure in the Intention-to-Treat (ITT) population. iv intravenous, mg/kg/day milligram/kilogram body weight/day.
Figure 3
Figure 3. Parasite clearance from peripheral blood.
Comparison of parasite clearance rates from peripheral blood in single (10 mg/kg) and multiple dose (7×3 mg/kg) regimens of AmBisome®. Data are from 5 consenting patients in each of the 10 mg/kg single-dose and multiple-dose arms.
See this image and copyright information in PMC

References

    1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7 (5) e35671 doi:10.1371/journal. pone.0035671 - DOI - PMC - PubMed
    1. Hailu A, Musa AM, Royce C, Wasunna M (2005) Visceral leishmaniasis: new health tools are needed. PLoS Med 2: e211. - PMC - PubMed
    1. WHO (2007) Fifth Consultative Meeting on Leishmania/HIV Coinfection, Addis Ababa, Ethiopia, 20–22 March 2007. World Health Organisation, WHO/CDS/NTD/IDM/20075.
    1. Reithinger R, Brooker S, Kolaczinski JH (2007) Visceral leishmaniasis in eastern Africa–current status. Trans R Soc Trop Med Hyg 101: 1169–1170. - PMC - PubMed
    1. Zijlstra EE, El-Hassan AM (2001) Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 95, Suppl 1: S27–S58. - PubMed

Publication types

Associated data